Related Experiment Videos
[Use of amitriptyline in attention deficit hyperactivity disorder]
A Guardiola1, A R Terra, L T Ferreira
1Departamento de Neurologia, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, Brasil.
Arquivos De Neuro-Psiquiatria
|February 10, 2000
Summary
Amitriptyline (AMI) improved motor persistence in children with attention deficit hyperactivity disorder (ADHD). This study compared AMI treatment against a placebo over 30 days, showing positive effects on specific neurological assessments.
Area of Science:
- Neuroscience
- Child Psychology
- Pharmacology
Background:
- Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
- Pharmacological interventions are often explored to manage ADHD symptoms.
- Amitriptyline (AMI) is a tricyclic antidepressant with potential neurological effects.
Purpose of the Study:
- To investigate the efficacy of amitriptyline (AMI) in treating attention deficit hyperactivity disorder (ADHD) in children.
- To assess the impact of AMI on specific cognitive and neurological functions relevant to ADHD.
Main Methods:
- A randomized controlled trial involving 25 children diagnosed with ADHD.
- Participants were divided into two groups: one receiving AMI (1.6 mg/kg/day) and a placebo group.
- Evaluations included the evolutive neurological evolution examination (ENE) and WISC subtests over a 30-day period.
Main Results:
- The group treated with amitriptyline (AMI) demonstrated significant improvement in motor persistence tests.
- No significant differences were noted in other WISC subtest performances between the groups.
Conclusions:
- Amitriptyline (AMI) may positively influence motor persistence in children with ADHD.
- Further research is warranted to explore the broader therapeutic potential of AMI in ADHD management.